Literature DB >> 7584477

Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system.

M S Hayden1, P S Linsley, M A Gayle, J Bajorath, W A Brady, N A Norris, H P Fell, J A Ledbetter, L K Gilliland.   

Abstract

Single-chain antibody molecules were expressed from modified eukaryotic expression vectors as individual protein domains encoded on interchangeable cDNA cassettes. Two different single-chain antibody derivatives were constructed by linking individual light- and heavy-chain variable domains. The first was specific for the L6 tumour-associated antigen and the second was specific for human CD3. Each single-chain variable domain was genetically fused with an Fc 'tag' and expressed as a fusion protein in a COS cell transient transfection system. These single-chain antibody derivatives demonstrated specific binding to cells expressing appropriate antigen and bound with affinities similar to native antibody. The CD3 single chain molecule mediated stronger activation of PLC gamma 1 and similar levels of T-cell proliferation compared with native antibody. A bispecific Fv single-chain cassette was created by fusing the expression cassettes encoding the binding domains for L6 and CD3 single-chain molecules using oligonucleotide primers encoding a short 27-residue 'helical' peptide linker. The CD3-L6 variable domains were fused to the Fc tag and expressed in COS cells. The CD3-L6FvIg bispecific fusion protein mediated adhesion between T cells and L6-positive tumour cells, and stimulated potent T-cell proliferation and cytotoxicity against tumour cells expressing the L6 antigen.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7584477

Source DB:  PubMed          Journal:  Ther Immunol        ISSN: 0967-0149


  10 in total

1.  Antibody fragments: hope and hype.

Authors:  Aaron L Nelson
Journal:  MAbs       Date:  2010-01-27       Impact factor: 5.857

2.  Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants.

Authors:  A A McCormick; M H Kumagai; K Hanley; T H Turpen; I Hakim; L K Grill; D Tusé; S Levy; R Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

Review 3.  Bispecific antibodies in cancer immunotherapy.

Authors:  Siqi Chen; Jing Li; Qing Li; Zhong Wang
Journal:  Hum Vaccin Immunother       Date:  2016-06-01       Impact factor: 3.452

4.  PCR cloning and sequencing of a CD3-specific monoclonal antibody.

Authors:  S Thirion; K Motmans; H Heyligen; J Raus; C Vandevyver
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

Review 5.  Redirection of cellular cytotoxicity. A two-step approach using recombinant single-chain Fv molecules.

Authors:  A J George; J A Titus; C R Jost; I Kurucz; P Perez; S M Andrew; P J Nicholls; J S Huston; D M Segal
Journal:  Cell Biophys       Date:  1995-06

6.  Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.

Authors:  Zhengxing Qu; David M Goldenberg; Thomas M Cardillo; Victoria Shi; Hans J Hansen; Chien-Hsing Chang
Journal:  Blood       Date:  2007-11-19       Impact factor: 22.113

7.  Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic.

Authors:  I A Haagen; W B de Lau; B J Bast; A J Geerars; M R Clark; B C de Gast
Journal:  Cancer Immunol Immunother       Date:  1994-12       Impact factor: 6.968

8.  Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients.

Authors:  Ulka Vaishampayan; Archana Thakur; Ritesh Rathore; Nicola Kouttab; Lawrence G Lum
Journal:  Prostate Cancer       Date:  2015-02-23

Review 9.  The making of bispecific antibodies.

Authors:  Ulrich Brinkmann; Roland E Kontermann
Journal:  MAbs       Date:  2017 Feb/Mar       Impact factor: 5.857

Review 10.  mRNA as novel technology for passive immunotherapy.

Authors:  Thomas Schlake; Andreas Thess; Moritz Thran; Ingo Jordan
Journal:  Cell Mol Life Sci       Date:  2018-10-17       Impact factor: 9.261

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.